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Background.Levosimendanisaninotropicdrugwithuniquepharmacologicaladvantagesinpatientswithacuteheartfailure.Scope
of this study is to determine whether longer infusion patterns without the hypotension-inducing loading dose could justify an
eﬀective andsafealternativeapproach. Methods.70patients admittedto the emergencies withdecompensated chronic heart failure
received intravenouslylevosimendan withouta loading dose up to 72 hours. Clinical parameters, BNP (Brain Natriuretic Peptide)
and signal-averaged-ECG data (SAECG) were recorded up to 72 hours. Results. The 48-hour group demonstrated a statistically
signiﬁcant BNP decrease (P<. 001) after 48 hours, which also maintained after 72 hours. The 72-hour group demonstrated a
bordeline decrease of BNP after 48 hours (P = .039),necessitating an additional 24-hour infusion to achieve signiﬁcant reduction
after 72 hours (P<. 004). SAECG data demonstrated a statistically signiﬁcant decrease after 72 hours (P<. 04). Apart from two
deaths due to advanced heart failure, no major complications were observed. Conclusion. Prolonged infusion of levosimendan
without a loading dose is associated with an acceptable clinical and neurohumoral response.
1.Introduction
Levosimendan is recognized as an inotropic drug used in
acute or decompensated chronic heart failure with innova-
tive characteristics. It is not a β-adrenergic agonist which
would have energy-consuming and proarrhythmic eﬀects.
It is rather a mild PDE inhibitor in clinical relevant doses
[1] and mainly a Ca-dependanttroponine-I sensitizer result-
ing in energetically beneﬁcial contractility of the cardiac
muscle. Furthermore, there is also an ATP-dependant K-
channel activation which causes peripheral vasodilation [2].
A cardioprotective mechanism via the ATP-K channels and
the phenomenon of preconditioning is also under research.
Pharmacokinetically, levosimendan acts for prolonged time,
since its two major metabolites OR-1855 and OR-1896 have
half-life time of 70–80 hours [3]. This pharmacological
proﬁle oﬀers an ideal medical option in acute heart failure
with preserved or borderline systolic blood pressure [4].
Standard pattern of infusion consists of a loading dose
and a continuous 24-hour i.v. infusion. In some cases, the
vasodilatory action causes an early hypotension resulting in
withdrawal of drug or coadministration with a β-agonist
with all the possible risks of this combination [5]. The
goal of this observational study was primarily to determine
whether a prolonged and beyond the 24-hour infusion
pattern without the loading dose could be eﬃcient and safe
for patients in acute or decompensated heart failure. For this
reason, weadministrated aprolongedlevosimendaninfusion
for 24, 48, or 72 hours creating three subgroups.
Clinical and neurohormonal responses were measured
with simple bedside parameters derived from physical exam-
ination [6] and serial measurements of BNP [7]a n dS A E C G .
Safety was determined by the presence of major or minor
complications and onset of new arrhythmias [8].2 Cardiology Research and Practice
2.Methods
2.1. Patients. Study population consisted of patients admit-
ted to hospital between March 2003 and December 2006
suﬀering from acute heart failure or decompensated chronic
heartfailure.TheclinicalstatusofthosepatientswasIIIorIV
according to the NYHA classiﬁcation. All patients were resis-
tant to optimal medical therapy and did need support of an
inotropic agent. Diagnosis of heart failure was conﬁrmed by
the contribution of physical examination, previous history,
but mainly by transthoracic echocardiography and thoracic
X-rays. Ejection fraction less than 45% in echocardiogram
was documented in all patients. Retrospective analysis of the
heart failure aetiology was performed.
As for the exclusion criteria, patients with an acute coro-
nary syndrome, cardiac shock with systolic blood pressure
under 85mmHg resistant to volume administration, hyper-
trophic cardiomyopathy, benign or life-threatening tachy-
arrhythmias with heart rate over 120/min, and electrolytic
abnormalities did not participate.
2.2.Study Protocol. The study protocolincludedquantitative
analysis in three diﬀerent subgroups of main population
determined by clinical evaluation after 24-hour intervals.
All participants took next to their standard medication
(diuretics, oxygen, ACEsor ARBs, digoxin, and β-blockersin
minor dose) an infusion of levosimendan of 0.05μg/min/Kg
uptitrated in two hours to 0.1μg/min/Kg for 24 hours. In
the interval, if there was no contraindication, the uptitration
could achieve the dose of 0.2μg/min/Kg.
24-hour and 48-hour time points after initial infusion
were crucial. It should be decided if levosimendan could be
stopped or continued according to bedside clinical criteria.
The subjective criterion of patient’s well-being and the ab-
sence of pathologic signs on auscultation of the pneumonal
areas or the absence of S3 gallop were cut points for the
discontinuation of levosimendan infusion. Patients, who
continuedtheinfusion, didsoforadurationof72hours.The
exclusion criteria of recruitment had the same power during
theinfusion time,sothatmanagement couldbesafe.Insome
complications, like hypotension or tachyarrhythmia, it was
up to investigator to treat the complication and to decide for
the next step of the study.
2.3. Measurements. All patients were measured for several
countable variables. Blood pressure and heart rate were de-
termined atbaseline and at24,48,and 72 hours, respectively.
A resting ECG was performed at the above-mentioned
time points conﬁrming also the possible arrhythmogenic
complications. In cases a conﬁrmation of heart failure was
needed, a transthoracic echo was performed.
As far for the neurohormonal response of the therapy,
we used measurements ofbrainnatriuretic peptide(BNP)by
means of the microspheric ELISA analysis (MEIA) method.
Blood samples of 6mL were taken at the beginning time
p o i n to ft h ei n f u s i o n ,a t4 8h o u r sa n da t7 2h o u r si n d e p e n d -
ently on the subgroup a patient belonged to.
After an addition of 0.1mL transylol for preserving pro-
teinmolecules,thesesampleswerecentrifugedat3000cycles/
min for 5 minutes. The serum taken was frozen on −20◦
Celsius for retrospective BNP measurements. BNP normal
range was assumed under the value of 100 pg/mL.
Onthestudy,asignal averagedECGwasused(Marquette
model 5000). P-wave ﬁltered, QRS ﬁltered duration, root
mean square voltage, the last 40msec, and the duration
of voltage <40μV at 40Hz were determined at baseline,
48 and 72 hours, respectively. Normal ranges of the above
mentioned variables are QRS ﬁltered duration <120msec,
RMS the last 40msec >20μV, and duration of low voltage
at 40Hz <38msec.
Conﬁrming an assumption of BNP response, we decided
to determine two cut points. Relative BNP decrease of >60%
was evaluated as a good neurohormonal response.
BNP decrease <20% or increase was evaluated as no
response. The values between the two cut points were char-
acterized as moderate responses.
Changes in QRS-ﬁltered duration observed in this clini-
cal study were evaluated with the assumption that variations
in QRS complex duration could represent respective varia-
tions in left ventricular dimensions. So, decreases in QRS-
ﬁltered duration >10msec were regarded as good response.
Increases in QRS-ﬁltered duration were evaluated as no
response and the values in between as moderate ones.
The well-being status was evaluated by means of clinical
examination and subjective conﬁrmation of the patient at
24 and 48 hours of infusion. This semicountable variable
was the determinator of continuation of levosimendan treat-
ment.
Major complications were conﬁrmed for the whole
duration of the study and a period of a month followed. A
continuous ECG monitoring during the infusion protocol
conﬁrmed the arrhythmias observed.
2.4. Statistics. Countable variables were demonstrated with
minimum, maximum, mean, and standard deviation values.
Diﬀerences in countable variables were evaluated with the
nonparametric paired t-test of Wilcoxon.
Correlation between countable variables was evaluated
with linear regression analysis. To conﬁrm a comparison
between the subgroups, we used the Kolmogorov-Smirnov
and the Mann-Whitney tests.
Uncountable variables were evaluated in a descriptive
manner and the correlation between them with the Chi-
square test accompanied by the Phi or Cramer’s V test. In
all the tests the null hypothesis is rejected at conﬁdence level
of 5%. SPSS.12 version statistical package was used.
2.5. Ethical Considerations. The protocol was approved by
the Institutional Review Board of our center and was per-
formed in accordance with institutional guidelines and the
Declaration of Helsinki. All patients gave written informed
consent before entering the study.Cardiology Research and Practice 3
Table 1:Demographicstatisticsatbaselineofthestudy population.
Mean ±St. dv. Range
Age (years) 63.7 ± 1.4 [36–88]
Mean arterial pressure (mmHg) 87.8 ±15.1 [72–126]
Heart rate (min−1) 76.5 ±10.5 [56–100]
BNP (pg/mL) 1104 ± 124 [51–4000]
Ejection fraction (%) 33.5 ± 6.3 [22–43.3]
P-wave duration (msec) 180 ± 10 [78–322]
QRS ﬁltered duration (msec) 149 ±4.1 [71–265]
Data are presented as Mean±Standard deviation.
Table 2: BNP and QRS ﬁltered duration variations after 72 hours.
Parameter
Response
Good Moderate Low
Relative BNP diﬀerence at % 44.3 24.3 28.6
72 hours NN = 31 N = 17 N = 20
Diﬀerence of QRS ﬁltered % 15.7 30.0 27.1
duration at 72 hours NN = 11 N = 21 N = 19
3.Results
3.1. Demographics. Descriptive variables are presented in
Table 1. The population consisted mainly of male partici-
pants (82.9%), not allowing to perform adequate sex-related
statistical analysis. Regarding the aetiology of the heart
failure, we observed a population with 64.3% suﬀering from
coronary artery disease and with 35.7% from nonischemic
dilated cardiomyopathy.
BNP mean baseline value was 1105pg/mL, conﬁrming
a study population with severe heart failure with low mean
ejection fraction at baseline (33.5 ± 6.3%) and high mean
enddiastolicleftventriculardiameter(6.81±0.81mm).Mean
P wave was elevated at baseline (180 ± 9.5msec)andmean
QRSduration ﬁltered (149±4.1msec)wasquitehigherthan
normal range, even if bundle branch block was present.
3.2. Neurohormonal Response. Relative BNP diﬀerence and
QRSdurationﬁltered at 72 hours are shown below (Table 2).
It is obvious by the data derived that using the speciﬁc
infusionpattern,therewasa68.6%ofgoodormoderateBNP
and a 45.7% of good or moderate QRS response.
Considering the two main end-point parameters overall,
there was a statistically signiﬁcant BNP decrease at 48 hours
after baseline (P<. 001), which continued at 72 hours, and a
signiﬁcantdecreaseofQRSﬁltereddurationat72hours(P =
.04). (Figures 1 and 2). However, crosstabulation of the QRS
duration and the BNP response did not show any statistically
signiﬁcant correlation (P>. 1).
Therewereestablishedthreesubgroupsdependingonthe
durationofinfusionof24hours(n = 14),48hours(n = 35),
or 72 hours (n = 21).
3.2.1. Levosimendan Infusion of 24h. The 24-hour infusion
subgroup had a mean percentage relative diﬀerence on BNP
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Figure 1: Changes of BNP after onset of levosimendan.
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Figure 2: Changes of ﬁltered QRS duration after onset of levosi-
mendan.
at 72 hours of 15.3% and mean diﬀerence on QRS duration
at 72 hours of 0.8msec per patient. There were no statistical
signiﬁcance in any measured parameter (P>. 1) according
to the Wilcoxon test for paired diﬀerences (Table 3).
3.2.2. Levosimendan Infusion of 48h. Patients with 48-hour
infusion had a statistically signiﬁcant decrease on BNP
beginning at 48 hours (P<. 0001), which continued at 72
hours (P<. 0001).
This ﬁnding indicates an enormous neurohormonal
response with 48-hour infusion of levosimendan without
loading dose. The mean percentage relative diﬀerence of
BNP at 72 hours showed a decrease of 43%, which is a4 Cardiology Research and Practice
Table 3: Demographic statistics of the three subgroups (24h, 48h,
and 72h infusion).
Infusion Start 48h 72h
BNP-
Concentration
(pg/mL)
24h-Group 1114 ±320 494 ±101
(P>. 1)
545 ±95
(P>. 1)
48h-Group 1215 ±193 748 ±151
(P<. 0001)
568 ±104
(P<. 0001)
72h-Group 912 ±159 601 ±18
(P<. 04)
535 ±29
(P = .004)
QRS Duration
(msecs)
24h-Group 151 ±6 159 ±12
(P>. 1)
169 ±5
(P>. 1)
48h-Group 145 ±6 159 ±8
(P>. 1)
140 ±6
(P = .06)
72h-Group 153 ±8 145 ±10
(P>. 1)
147 ±6
(P = .05)
Data are presented as Mean±Standard Deviation.
quite acceptable percent. QRS duration had on average a
borderline signiﬁcant decrease at 72 hours of −10.96msecs
per patient (P = .065), which might indirectly indicate a
decrease of left ventricular dimensions.
3.2.3. Levosimendan Infusion of 72h. Patients with 72-hour
infusion had a borderline signiﬁcant decrease on BNP begin-
ning at 48 hours (P = .039) and a statistically signiﬁcant
decrease at 72 hours (P<. 004). This ﬁnding shows a
good neurohormonal response with 48-hour infusion of
levosimendan without loading dose with the necessity to
follow 24-hour infusion additionally, so that the decrease
could achieve a signiﬁcant range. Mean percentage relative
diﬀerence of BNP at 72 hours was 31%. QRS ﬁlt duration
had on average a borderline signiﬁcant decrease at 72 hours
of −7.4msecs per patient (P = .049).
Trying a general correlation between the countable
parameters ofdiﬀerence of QRS ﬁltered duration at 72 hours
and BNP relative diﬀerence at 72 hours, there was a linearity
only in cases with adverse response for the two variables
(R-squared=0.01). Crosstabulation analysis of the two 48-
and 72-hour infusion patterns demonstrated that at 48-hour
infusion there was an obvious correlation between good
QRS responders and good BNP responders (P value of χ-
square test=.05). This statistical result was determined by
the respective adjusted residuals of the data analysis.
At 72-hour infusion, the correlation was biased with
non-BNP responders to have also a moderate QRS ﬁltered
duration response (P>. 1).
According to the Kolmogorov-Smirnov test and the
Mann-Whitney analysis, thedemographicsoftwosubgroups
of the population were compared. Without diﬀerences on
the characteristics, those who have taken 48-hour infusion
demonstrated at least good or moderate QRS ﬁltered
duration—at acceptableBNP—response, representing asub-
population with good neurohormonal proﬁle (Figure 3).
3.3. Safety. As for the complications, there were not patients
who had to discontinue the study due to hypotension
or other minor complication. Two patients died due to
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Figure 3: Diﬀerences of BNP response and ﬁltered QRS duration
between infusion groups.
advanced heart failure (asystole without successful reani-
mation). New onset of atrial ﬂutter, atrial ﬁbrillation or
ventricular tachycardia was not observed, indicating a study
population with low short-term arrhythmogenic proﬁle
according to the continuous ECG monitoring.
All patients survived achieved a weaning status by
inotropic agents without the necessity of withdrawal until
their discharge. Within a period of a month, one patient
waspresentedwithacuterenalexacerbation,andthreeothers
needed to be rehospitalised for exacerbated heart failure.
4.Discussion
In this study, we tried to demonstrate eﬃciency and safety
of an alternative infusion pattern of levosimendan in acute
heart failure. The critically illp a t i e n t so ft h i sc o n d i t i o nh a v e
most of the time a borderline preserved systolic pressure.
So, it is important to prevent the patient from hypotension,
which could induce hypoperfusion. Levosimendan has on
start an enormous peripheral vasodilatory eﬀect, which
causes hypotension [9].
In this view, participants were not given the loading dose
at the beginning, but a continuous dose was administrated
up to 72 hours depended on the clinical response.
BNPis widely recognized as a therapeutictool of respon-
siveness in patients with heart failure [10]. In our study, we
used BNP as a reliable marker of eﬃciency [11].Cardiology Research and Practice 5
It was obvious from the data analysis that those patients
who were given 72-hour infusion had the necessity for such
a long infusion. They did not achieve clinical improvement
at 48 hours, so they had to continue with another 24-
hour infusion. The population studied were patients with
advanced heart failure, since mean value was generally above
1000pg/mL. This means that the percent of decrease of BNP
was, respectively, not so enormous likein othertrials [12], in
which the mean value was about 500–800pg/mL. We think
that the achieved mean values of 31–43% are acceptable
improvement [13], concerning that all patients survived did
nothavesymptoms orre-exacerbationoftheirclinicalstatus.
The other basic bound of our study was the inves-
tigation of safety of such infusion patterns. As for the
complications observed, there was no indication that we had
arrhythmogenic eﬀect of the agent. The two deaths were
due to advanced heart failure and could be accepted by the
condition of acute heart failure [14].
The signal averaged ECG is an examination which has
a good speciﬁcity in predicting monomorphic ventricular
tachycardia in patients with chronic heart failure. Its power
is obvious in patients after myocardial infarct [15]. There
are also studieswith patientsofdilatedcardiomyopathy [16],
which mention the role of signal-averaged ECG. However, in
the last years, the role of this examination has diminished
[17].
The scope was to show that levosimendan did not at
least change the parameters of this examination, so that a
neutral eﬀect could be conﬁrmed. Indeed, the study showed
that in good BNP responders there was a subpopulation
whose QRS ﬁltered duration not only was unchanged but
also decreases. The ﬁnding of this observation cannot be
evaluated exactly but indicates a subpopulation with good
clinicalandneurohormonalresponse.Furtherstudiesshould
beconductedtoinvestigate thecorrelationbetweenBNPand
ﬁltered QRS duration variations.
Considering the results of this study, it could be said that
levosimendan is an inotropic drug, which allows an infusion
of more than 24 hours. There is also an opposed opinion
[18], which supports that there is no need of prolonged
infusions, since the metabolites of levosimendan have long
half-life period. The problem is that sometimes patients
admitted are critically ill and the target of treating them
eﬃciently is diﬃcult to achieve.
We need an inotropic agent like levosimendan with
an acceptance of β-blocker coadministration, or at least
at low doses, with non-β-agonist eﬀect and energetically
beneﬁcial. Furthermore, at this clinical condition, a drug-
induced hypotension could be unnecessary. So, patterns
without loading dose could be beneﬁcial.
Limitations of the study are its design, which does not
have perspective analysis and randomization of groups in
an objective manner. It is an observational study with the
additional limitation of small period of followup of the
variables measured.
Another limitation is the absence of hemodynamic data
[19, 20], which could support adequately the scope of the
study. This could be the goal of a future study in the same
way of using alternative infusion patterns.
The subgroup observed in this study with the beneﬁcial
proﬁle should be followed in time with the hope to stratify
the cumulative risk of mortality or morbidity in heart failure
[21].
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